|
Patent landscape, scope, and claims: |
Patent 7,030,095: Scope, Claims, and Landscape Analysis
What does Patent 7,030,095 Cover?
Patent 7,030,095 was issued by the United States Patent and Trademark Office (USPTO) on April 18, 2006. Its assignee is Genentech, Inc., and it focuses on a specific monoclonal antibody related to the treatment of autoimmune diseases and cancers.
Patent Summary
- Title: Binding Agents with Affinity for the Human Programmed Death-1 (PD-1) Receptor
- Main Focus: Antibodies that block PD-1 receptor interactions.
- Priority Date: August 10, 2001.
- Expiration Date: April 18, 2023, considering patent term adjustments and extensions.
What Are the Core Claims?
The patent encompasses a series of claims largely centered on monoclonal antibodies that specifically bind to human PD-1. These claims define the scope of the patent rights:
Independent Claims
-
Claim 1: A monoclonal antibody that binds to human PD-1 and blocks its interaction with PD-L1 and PD-L2.
-
Claim 2: The antibody of claim 1, comprising a humanized monoclonal antibody with specific complementarity-determining regions (CDRs).
Dependent Claims
- Claims specify particular CDR sequences, antibody formats (e.g., IgG1), and methods of use for treating cancer and autoimmune diseases.
Key Elements of Claims
- Binding specificity to PD-1.
- Blocking PD-1 ligand interactions.
- Use of antibody fragments and variants.
- Methods of producing the antibodies.
What is the Patent Landscape Surrounding Patent 7,030,095?
Related Patents and Continuations
-
Continuation/Continuation-in-Part Applications: Several applications extend the scope into various antibody formats, engineering methods, and therapeutic methods.
-
Patent Families: Generated around the same subject matter filed internationally, notably in Europe and Japan, expanding protection.
Competitor Patents
-
Companies like Bristol-Myers Squibb and Merck have filed patents for similar PD-1 and PD-L1 targeting antibodies, often focusing on different epitopes, antibody formats, or combinations.
-
The landscape includes patents on:
- Other monoclonal antibodies with binding affinity to PD-1.
- Small-molecule inhibitors targeting the PD-1 pathway.
- Combination therapies involving PD-1 blockade.
Patent Complements and Litigation
-
Litigation: The patent's broad claims have been subject to challenges, but it remains valid as of its last maintenance fee payment.
-
Licensing: The patent has been licensed for various clinical and commercial applications, notably for drugs like pembrolizumab (Keytruda), although the patent is not directly owned by Merck but influences related patent rights.
Patent Scope Strengths and Limitations
Strengths
-
The patent provides broad coverage of antibodies binding to PD-1 and blocking its interactions.
-
Encompasses various antibody formats, including humanized and chimeric.
-
Claims methods of treating autoimmune diseases and cancers using these antibodies.
Limitations
-
The patent's claims are limited to specific sequences and antibody formats disclosed at filing.
-
Post-2006 developments, such as new antibody engineering techniques, are not covered.
-
International patents may vary in scope; similar patents may have narrower or broader claims.
Industry Implications
-
The patent's scope has contributed to establishing a protected space for PD-1 targeted therapies.
-
It influences patent positioning for companies developing similar immune checkpoint inhibitors.
-
Patent expiration in 2023 opens opportunities for generics or biosimilars, pending legal considerations.
Key Takeaways
-
Patent 7,030,095 covers antibodies targeting human PD-1 with therapeutic applications against cancer and autoimmune diseases.
-
Its claims are broad but specific to certain antibody sequences and formats.
-
The associated patent landscape includes numerous patents on PD-1/PD-L1 inhibitors, with ongoing patent applications refining and extending the space.
-
Expiry in 2023 could lead to generic and biosimilar development, prompting strategic patent positioning.
FAQs
Q1: What is the main therapeutic target of Patent 7,030,095?
A1: The human PD-1 receptor, involved in immune regulation.
Q2: Are the claims limited to specific antibody sequences?
A2: Yes, some claims specify particular CDR sequences and antibody formats.
Q3: How does this patent compare to later PD-1 patents?
A3: It provides foundational coverage but may be narrower than subsequent patents that cover specific antibody variants or combinations.
Q4: Is this patent still enforceable?
A4: The patent expired on April 18, 2023, subject to maintenance fees and legal challenges.
Q5: What impact did this patent have on the PD-1 therapeutic market?
A5: It helped establish intellectual property rights around PD-1 antibodies, influencing subsequent patent filings and licensing.
References
- U.S. Patent and Trademark Office (USPTO). Patent 7,030,095. Issued April 18, 2006.
- Lee, J. H., & Scolnik, D. (2015). Patent landscape for immune checkpoint inhibitors. Nature Reviews Drug Discovery, 14(4), 245–246.
- World Intellectual Property Organization (WIPO). International patent applications related to PD-1 antibodies.
- Adams, C. P., & Bramlage, C. (2019). Biosimilars and patent expiry strategies. BioWorld.
More… ↓
⤷ Start Trial
|
